Provided are: a peptide effective in preventing cell damage having an amino acid sequence in the first sequence in the sequence listing； and a pharmaceutical composition for preventing cell damage comprising the peptide as an active ingredient. The peptide according to the present invention not only has far better physiological activity in its protective action on various cells than does existing natural human erythropoietin but also has a markedly more simple structure than does natural human erythropoietin, and thus the peptide easily passes across the tissue-blood barrier and is economic in that production costs are reduced which makes the peptide advantageous. Consequently, a pharmaceutical composition comprising the peptide according to the present invention as an active ingredient is efficacious in the prevention or treatment of, inter alia, neurodegenerative diseases and acute and chronic kidney function impairment, such as stroke, mechanical damage or ischemic damage of the nervous system, myocardial infarction, diabetes, cardiac insufficiency, peripheral vascular disorders, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, glaucoma, dementia, Parkinson's disease and Lou Gehrig's disease.La présente invention concerne un peptide efficace dans la prévention des dommages cellulaires, possédant une séquence d'acides aminés dans la première séquence de la liste des séquences. L'invention porte également sur une composition pharmaceutique destinée à prévenir les dommages cellulaires, comprenant ledit peptide en tant que principe actif. Le peptide de l'invention présente non seulement une activité physiologique bien supérieure à celle de l'érythropoïétine humaine naturelle en termes d'action protectrice sur les diverses cellules, mais également une structure considérablement plus simple ； ainsi, ce peptide traverse facilement la barrière sanguine tissulaire. Par ailleurs, il se révèle économique, car les coûts de production sont réduits, ce qui le r
